RT Journal Article
SR Electronic
T1 SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.04.22273314
DO 10.1101/2022.04.04.22273314
A1 Huygens, Sammy
A1 Hofsink, Quincy
A1 Nijhof, Inger S
A1 Goorhuis, Abraham
A1 Kater, Arnon P
A1 te Boekhorst, Peter AW
A1 Swaneveld, Francis
A1 Novotný, Věra MJ
A1 Bogers, Susanne
A1 Welkers, Matthijs RA
A1 Papageorgiou, Grigorios
A1 Rijnders, Bart J
A1 Heijmans, Jarom
YR 2022
UL http://medrxiv.org/content/early/2022/04/05/2022.04.04.22273314.abstract
AB Background Severely immunocompromised patients are at risk for severe COVID-19. Benefit from convalescent plasma in these patients is suggested but data from randomised trials are lacking. The aim of this study is to determine efficacy of SARS-CoV-2 hyperimmune globulin (“COVIG”) in treatment of severely immunocompromised, hospitalised COVID-19 patients.Methods In this randomised, controlled, double-blind, multicentre, phase 3 trial, severely immunocompromised patients who were hospitalised with symptomatic COVID-19 were randomly assigned (1:1) to receive 15 grams of COVIG or 15 grams of intravenous immunoglobulin without SARS-CoV-2 antibodies (IVIG, control). Patients included were solid organ transplant patients with three drugs from different immunosuppressive classes or patient with disease or treatment severely affecting B-cell function. Patients that required mechanical ventilation or high flow nasal oxygen were excluded. All investigators, research staff, and participants were masked to group allocation. The primary endpoint was occurrence of severe COVID-19 evaluated up until day 28 after treatment, defined as the need for mechanical ventilation, high-flow nasal oxygen, readmission for COVID-19 after hospital discharge or lack of clinical improvement on day seven or later. This trial is registered with Netherlands Trial Register (NL9436).Findings From April, 2021, to July, 2021, 18 participants were enrolled at three sites in the Netherlands; 18 patients were analysed. Recruitment was halted prematurely when casirivimab/imdevimab became the recommended therapy in the Dutch COVID-19 treatment guideline for seronegative, hospitalised COVID-19 patients. Median age was 58 years and all but two were negative for SARS-CoV-2 spike IgG at baseline. Severe COVID-19 was observed in two out of ten (20%) patients treated with COVIG compared to seven of eight (88%) in the IVIG control group (p = 0·015, Fisher’s exact test).Interpretation COVIG reduced the incidence of severe COVID-19 in severely immunocompromised patients, hospitalised with COVID-19. COVIG may be a valuable treatment in this patient group and can be used when no monoclonal antibody therapies are available.Funding The Netherlands Organisation for Health Research and Development, Sanquin Blood Supply Foundation.Competing Interest StatementFS and VN work at Sanquin Blood Supply Foundation. Prothya (former Sanquin Plasma Products) generated COVIG and IVIG. The work was funded by an unrestricted grant from Sanquin Blood Supply Foundation.Clinical TrialNL9436Funding StatementThe study was funded by The Netherlands Organisation for Health Research and Development and an unrestricted grant from Sanquin Blood Supply Foundation. FS and VN work at Sanquin Blood Supply Foundation. Prothya (former Sanquin Plasma Products) generated COVIG and IVIG.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Amsterdam UMC location University of Amsterdam, Erasmus University Medical Center, and St. Antonius Ziekenhuis Nieuwegein gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.